focus -WSS

focus

author：explore 2025-10-01 22:16:31 - browse：51

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Medicare Advantage today, explained in one chart

knowledge

WSS

The Sacklers, horror, and ‘The Fall of the House of Usher’

Readout Newsletter: Merck, J&J, and long Covid

How digital therapeutics firms are pivoting after Pear's bankruptcy

FDA clears AI tool for detecting skin cancer

STAT Executive Editor Rick Berke on STAT's 8th birthday

FDA clears AI tool for detecting skin cancer

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Cancer drug shortages should be causing more outrage

My yearlong odyssey to get my son’s ADHD medication covered

Dobbs anniversary: the lost opportunity of abortion as health care

A clever new way to fix Medicaid and graduate medical education

Alkermes shareholders re

Diversify hospital leadership teams to protect BIPOC patient health

How one medical school became remarkably diverse

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Peter Hotez and the public health issue of online harassment

Abortion clinic in Cancun will cater to Americans

focus

Eli Lilly, Pfizer, and others want in on the online prescription market

Study: New antibiotic targets gonorrhea as well as last existing drug

Will General Catalyst be the first of many hospital takeovers?

Biotech incubator Curie.Bio graduates its first startup

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

The tragedy of Johnson & Johnson’s Covid vaccine

Wikipedia

knowledge

knowledge

explore